Physician profile
Rajeev Batra
NPI 1003918228
$7,082.30
in general payments reported to CMS, 2019-2025
47 companies · $1,177 in 2025
The $1,177 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,185 · 2020: $207 · 2021: $660 · 2022: $1,364 · 2023: $1,265 · 2024: $1,223 · 2025: $1,177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,608 · Education: $58.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,607.73 |
| Education | $58.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $848.10 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $709.71 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $589.59 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $510.85 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $443.90 | 2019-2025 | |
| Pfizer INC. | $408.69 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $369.91 | 2022-2025 | |
| Amgen INC. | $356.63 | 2019-2025 | Repatha, Otezla, Otezla |
| Medtronic, INC. | $347.58 | 2022-2023 | Closurefast |
| Glaxosmithkline, LLC. | $261.81 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbott Laboratories | $235.21 | 2021-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $209.75 | 2019-2025 | Verquvo |
| Amarin Pharma, INC. | $151.75 | 2019-2022 | |
| Boston Scientific Corporation | $148.47 | 2023-2024 | Varithena Administration Pack |
| E.R. Squibb & Sons, L.L.C. | $148.11 | 2019-2025 | Camzyos, Eliquis |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajeev Batra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.